Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
|
31335987 |
2020 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MTT assay revealed that miR-130b modulated cell growth. qRT-PCR revealed an inverse correlation between miR-130b and PTEN in RCC.
|
31195398 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies verified that PTEN deficiency effectively attenuated the ability of AFAP1-AS1 in promoting ccRCC cell proliferation, invasion, migration, and EMT.
|
30832752 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression.
|
31592114 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our findings have indicated that multiple genes and pathways may play a crucial role in PTEN mutation ccRCC, offering candidate targets and strategies for PTEN mutation ccRCC individualized treatment.
|
31139560 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression pattern of tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten (PTEN) and phosphatase and tensin homolog deleted on chromosome ten/phosphatidylinositol3-kinase/protein kinase B (PTEN/PI3K/AKT) cell signaling pathway in renal cell carcinoma (RCC) were investigated in children.
|
30655739 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of PTEN-Long in serum of patients with nephritis, renal cell carcinoma (RCC) as well as normal controls, and in serum and renal tissues of mice were measured by western blotting.
|
30680021 |
2019 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the purpose of this work was to (1) evaluate the expression of EMT markers: ZEB2, vimentin, N-cadherin, TWIST, PTEN, survivin, E-cadherin, Ki-67 and GLUT-1, (2) assess mutation status of two genes: PIK3CA and KRAS, and (3) investigate the potential relationships between the studied biomarkers and clinicopathological factors in clear-cell renal cell carcinoma (ccRCC).
|
30569446 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT.
|
29946925 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PTEN expressing RCC cell line A498 and the PTEN deficient 786-O cell line were stably transfected with the PTEN-Δ or PTEN transcript.
|
29954386 |
2018 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, we conclude that DLX6-AS1 promotes renal cell carcinoma development via regulation of miR-26a/PTEN axis.
|
28881158 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, the findings indicated for the first time that miR-193a-3p functions as a tumor-promoting microRNA by directly targeting PTEN in renal cell carcinoma.
|
28639901 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This meta-analysis suggests that PTEN expression is of limited value in predicting the prognosis of patients with RCC for OS and PFS via immunohistochemistry staining analysis; and that for DSS, low PTEN expression is significantly associated with an unfavorable outcome.
|
28672019 |
2017 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
miR‑205 suppresses cell proliferation, invasion, and metastasis via regulation of the PTEN/AKT pathway in renal cell carcinoma.
|
27498834 |
2016 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study suggested that the miR-22/PTEN axis may be considered a novel therapeutic target in RCC.
|
27082730 |
2016 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In ccRCC tissues, expression levels of SMAD4 and PTEN were negatively correlated with expression level of miR-19a, revealing that miR-19a suppressed the expression of SMAD4 and PTEN in ccRCC patients. miR-19a overexpression significantly suppressed the expression of SMAD4 and PTEN in vitro, further verifying that SMAD4 and PTEN were the target genes of miR-19a in ccRCC cells.
|
27779660 |
2016 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
|
27779645 |
2016 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We excluded the samples that had any of the five high-confidence driver genes (VHL, BAP1, SETD2, PTEN and KDM5C) reported in ccRCC to avoid their possible influence in our results.
|
27556922 |
2016 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Gain of function experiments showed overexpression of PTEN-Long in the ccRCC cell line 786-0 suppressed PI3K-Akt signaling, inhibited cell proliferation, migration and invasion, and eventually induced cell death.
|
25714556 |
2015 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Changes in PTEN and CDKN2A gene sets were associated with worsened prognosis of ccRCC.
|
25853938 |
2015 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This was further verified in CCRCC tissue specimens from patients The results of the present study suggested that loss of PTEN, which deactivated Akt/HDM2 signaling followed by degradation of p53, may contribute to the development of etoposide resistance in CCRCC.
|
25954860 |
2015 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.
|
25401301 |
2015 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of 416 patients with clear cell renal cell carcinoma 11 (2.6%) had biallelic PTEN loss and 69 (16.6%) had monoallelic loss.
|
24704020 |
2014 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTENP1 and PTEN are direct targets of miRNA miR21 and their expression is suppressed by miR21 in ccRCC cell lines. miR21 expression promotes ccRCC cell proliferation, migration, invasion in vitro, and tumor growth and metastasis in vivo.
|
25249556 |
2014 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because loss of PTEN can activate mTOR and mTOR inhibitors are Food and Drug Administration approved to treat renal cell carcinoma, these agents have clinical potential in renal cell carcinoma associated with Cowden syndrome.
|
23764071 |
2013 |